Food and medicine homologous composition for reducing blood sugar
Patent Information
- Application Number
- CN202411497791.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2025-01-28
Smart Images
Figure CN119367465A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a food-drug homologous composition for lowering blood sugar. Background Art
[0002] Diabetes is a chronic disease mainly caused by insufficient insulin secretion or impaired insulin utilization by the human body, which leads to persistently high blood sugar levels. The main types of diabetes include type 1 diabetes and type 2 diabetes. Type 1 diabetes is usually caused by the destruction of beta cells in the pancreas by the autoimmune system, resulting in absolute insulin deficiency. Type 2 diabetes is mainly caused by insulin resistance and relative insulin deficiency. In addition, some diabetes is caused by the combined effects of genetic factors, environmental factors, and lifestyle (such as improper diet, lack of exercise, obesity, etc.).
[0003] The treatment of diabetes mainly includes drug therapy, exercise therapy, diet therapy, blood sugar monitoring, diabetes education and psychological improvement. Among them, diet is an important means of daily management of diabetes, and dietary intake is closely related to blood sugar fluctuations. Blood sugar monitoring is also an important means of controlling diabetes. Therefore, slowing down post-meal blood sugar fluctuations is an effective and important method for daily management of diabetes. Current drug therapy is also mainly aimed at lowering blood sugar, but there are still a large number of people who fail to effectively manage blood sugar under the intervention of Western medicine alone.
[0004] Traditional Chinese medicine has a long history of treating diabetes. It has the advantages of treating both the root cause and the symptoms and regulating the whole body. It can not only lower blood sugar, but also regulate and improve the physical condition. The theory of the homology of food and medicine comes from the traditional culture of traditional Chinese medicine. Its varieties are essentially edible Chinese medicinal materials. Because they are both medicinal and edible, they are mostly used in medical care in the form of food supplements and medicated diets, especially for chronic diseases such as diabetes. It has both regulatory and "strengthening" effects, and is highly safe and suitable for long-term use. However, the current treatment effect of traditional Chinese medicine on diabetes is not obvious, and the formula needs to be improved. Summary of the invention
[0005] The purpose of the present invention is to provide a food-drug homologous composition for lowering blood sugar.
[0006] A food-drug homologous composition for lowering blood sugar comprises the following components: polygonatum, kudzu root, polygonatum odoratum, mulberry leaf, bergamot, citron, mulberry, ebony, daisy flower and spiny jujube seed.
[0007] Preferably, the following components are included in parts by weight: 5-10 parts of polygonatum, 5-10 parts of kudzu root, 5-10 parts of polygonatum, 3-10 parts of mulberry leaves, 3-5 parts of citron, 3-5 parts of mulberry, 3-5 parts of ebony, 3-5 parts of daidai hua, and 3-5 parts of spiny jujube seeds.
[0008] More preferably, the composition comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum, 5 parts of mulberry leaf, 4 parts of citron, 4 parts of mulberry, 4 parts of ebony, 4 parts of daidai hua, and 4 parts of spiny jujube seed.
[0009] Furthermore, the raw material medicine is decocted and extracted with water to prepare an oral solution.
[0010] Furthermore, the raw materials are crushed into fine powders and mixed to form powders.
[0011] Furthermore, the raw material drug is crushed into fine powder and filled into capsules to prepare capsules.
[0012] Furthermore, the raw material drug is crushed into fine powder and compressed into tablets.
[0013] Furthermore, the raw material drug is extracted by decocting with water, and the extract is concentrated to form granules to form granules; or, the raw material drug is extracted by decocting with water, and the extract is concentrated to form granules, and then encapsulated to form capsules; or, the raw material drug is extracted by decocting with water, and the extract is concentrated to form granules, and then compressed to form tablets.
[0014] A food comprising the food-drug homologous composition or an extract thereof; the food is a liquid beverage, a solid beverage, a rice sauce, a compressed candy, a jelly or a soft candy.
[0015] The invention has the beneficial effects as follows: the prescription is prepared by combining 10 Chinese medicinal herbs including polygonatum, kudzu root, polygonatum odoratum, mulberry leaf, bergamot, citron, mulberry, black plum, daidaihua and spiny jujube seed. The monarch herb polygonatum can invigorate qi and nourish yin, strengthen the spleen, moisten the lungs and benefit the kidneys; the kudzu root can promote fluid production and quench thirst; the polygonatum odoratum can nourish yin and moisten dryness, promote fluid production and quench thirst; the assistant herb mulberry leaf can clear the lungs and moisten dryness, clear the liver and improve eyesight; the bergamot can soothe the liver and regulate qi, harmonize the stomach and relieve pain, dry dampness and resolve phlegm; the citron can soothe the liver and regulate qi, relieve fullness and resolve phlegm; the mulberry can nourish yin and nourish blood, promote fluid production and moisten dryness. The prescription can soothe the liver and regulate qi to enhance the qi-invigorating effect of the monarch herb, and can also promote fluid production and moisten dryness, nourish yin and nourish blood to enhance the yin-nourishing effect of the monarch herb. The adjuvant black plum can restrain the lungs, astringe the intestines, and promote the production of body fluids; the daidaihua can regulate qi and relieve chest tightness; the jujube seeds can nourish the heart and liver, calm the mind and tranquilize the nerves, restrain sweat, and promote the production of body fluids. They can enhance the function of regulating qi, promote the production of body fluids to treat thirst, restrain the lungs to replenish lung qi, and nourish the yin and blood of the heart and liver. The whole prescription can not only adjust the body's qi and yin deficiency, promote the production of body fluids and quench thirst, but also reduce the blood sugar-raising effect caused by carbohydrates. It has the advantages of treating both the symptoms and the root causes of diabetes and overall regulation. Among them, the components of citron, black plum, daidaihua, and jujube seeds have a synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 Metascape was used to conduct KEGG analysis on the targets of food-drug homologous prescriptions.
[0017] Figure 2Metascape was used to conduct BP analysis on the targets of food-drug homologous prescriptions.
[0018] Figure 3 Metascape was used to perform MF analysis on the targets of food-drug homologous prescriptions.
[0019] Figure 4 This is a CC analysis of the targets of food-drug homologous prescriptions using Metascape.
[0020] Figure 5 This is the effect of the food-drug combination on the glucose-raising effect of starch in mice. In the figure, compared with the starch group, *P<0.05, **P<0.01. DETAILED DESCRIPTION
[0021] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0022] Example 1
[0023] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum, 5 parts of mulberry leaves, 4 parts of citron, 4 parts of mulberry, 4 parts of ebony, 4 parts of daikon flos, and 4 parts of spiny jujube seeds.
[0024] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0025] Example 2
[0026] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 6 parts of polygonatum, 6 parts of kudzu root, 6 parts of polygonatum odoratum, 4 parts of mulberry leaf, 3 parts of bergamot, 3 parts of citron, 3 parts of mulberry, 3 parts of ebony, 3 parts of daidai hua, and 3 parts of spiny jujube seed.
[0027] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0028] Example 3
[0029] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 10 parts of polygonatum, 10 parts of kudzu root, 10 parts of polygonatum odoratum, 8 parts of mulberry leaves, 5 parts of bergamot, 5 parts of citron, 5 parts of mulberry, 5 parts of ebony, 5 parts of daisy flower, and 5 parts of spiny jujube seeds.
[0030] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0031] Comparative Example 1
[0032] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum, 5 parts of mulberry leaves, 4 parts of bergamot, 8 parts of citron, 4 parts of mulberry, 4 parts of daikon radix, and 4 parts of spiny jujube seeds.
[0033] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0034] Comparative Example 2
[0035] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum odoratum, 5 parts of mulberry leaf, 4 parts of citron, 4 parts of mulberry, 8 parts of ebony, 4 parts of daisy flower, and 4 parts of spiny jujube seed.
[0036] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0037] Comparative Example 3
[0038] A food-drug combination for lowering blood sugar comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum odoratum, 5 parts of mulberry leaves, 4 parts of bergamot, 4 parts of citron, 4 parts of mulberry, 4 parts of ebony, and 8 parts of daidaihua.
[0039] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0040] Comparative Example 4
[0041] A food and medicine composition for lowering blood sugar comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum, 5 parts of mulberry leaf, 4 parts of bergamot, 4 parts of citron, 4 parts of mulberry, 4 parts of ebony, and 8 parts of spiny jujube seed.
[0042] All medicinal materials were purchased from Beijing Tong Ren Tang Dashilan Pharmacy. The medicines to be decocted were soaked first for 60 minutes. The amount of water used at the beginning of decoction was 4 cm above the medicine surface. The medicines were decocted twice. When the medicines were first decocted, they were boiled and then decocted for 30 minutes. The second decocting time was 20 minutes. The medicines were stirred 3 times during the decocting process. The two decoctions were mixed, and the water extract of the food and medicine formula was quantitatively concentrated using a rotary evaporator.
[0043] Experimental Example 1: Network Pharmacology Formula Interpretation
[0044] 1. Target-effective ingredient network analysis of food-drug homologous prescriptions
[0045] The network pharmacology method was used to conduct a joint analysis of the Chinese medicine-active ingredients-targets in the prescription to observe the role of the active ingredients of the Chinese medicine in the overall efficacy of the prescription. The Cytoscape software was used to visualize the target Degree value, and the interactive correlation between the active ingredients and the target was observed. The nodes represent the association between the active ingredients and the target proteins. The more nodes are connected to the nodes in the network, the larger the Degree value, and the larger the node, the more important it is. Among them, the top 20 active ingredients with the highest Degree value in the network are: B, D, E, C, F, A, Y4-20, Y1-2, Y9-2, Y2-1, Y4-24, Y4-21, Y7-2, Y5-4, Y4-13, Y1-7, Y10-1, Y5-2, Y1-6, and Y10-6. The specific names and Chinese medicine affiliations are listed in Table 1. The top 10 targets with the highest degree value in this network are PTGS2, PTGS1, HSP90, NCOA2, SCN5A, PGR, CALM, AR, PIK3CG, and PPARG. It can be concluded that each Chinese medicine contains multiple components, and most of each component is not only derived from one Chinese medicine, which shows that the Chinese medicines in the formula give full play to the role of mutual synergy and complementation, and prevent and treat diabetes through the combined effect of multiple components and multiple targets.
[0046] Table 1 The 20 chemical components with the highest degree values in food-drug homologous formulas
[0047]
[0048]
[0049] 2. Screening of core targets of food-drug homology formula for diabetes
[0050] The selected food-drug homologous formula and diabetes targets were analyzed using the STRING database and visualized using Cytoscape to obtain the formula target PPI network diagram, in which 262 targets were connected by 5335 relationships, and the diabetes target PPI network had 1211 targets connected by 13492 relationships. After merging the two PPI networks, a network consisting of 143 targets connected by 1240 relationships was formed. The core targets of food-drug homologous formula B acting on diabetes were screened using the median of twice the degree value, that is, degree>26. The top 10 targets were IL6, AKT1, TP53, IL1B, TNF, EGFR, JUN, CASP3, MMP9, and CTNNB1.
[0051] 3. KEGG and GO functional enrichment analysis of food-drug homologous prescriptions
[0052] Through network pharmacology analysis, a total of 262 targets of the formula were obtained; a total of 1701 targets of diabetes were screened through databases such as OMIM, Genemap, and Genecard; the targets of the formula and the targets of diabetes were fitted, and a total of 143 duplicate genes were obtained. The above 143 potential targets were analyzed by GO and KEGG using the Metascape database.
[0053] KEGG pathway enrichment analysis was performed with P < 0.05 as the screening condition. The main signal pathways enriched included cancer pathways, lipid and atherosclerosis, TNF signaling pathway, HIF-1 signaling pathway, chemical carcinogenesis-receptor activation, diabetic cardiomyopathy, malaria, insulin resistance, platinum drug resistance, NF-kappa B signaling pathway, AMPK signaling pathway, etc. This shows that the formula can play a therapeutic role in diabetes through multiple pathways ( Figure 1 ).
[0054] GO enrichment analysis was performed with P < 0.05 as the screening condition. In terms of BP, the active ingredients of the formula were mainly involved in cellular response to lipid, response to hormone, response to oxidative stress, response to nutrient levels, positive regulation of cell migration, response to xenobiotic stimulus, cellular response to cytokine stimulus, negative regulation of cell differentiation, positive regulation of phosphorus metabolic process, cellular response to organic cyclic compound, etc. Figure 2 ).
[0055] In terms of MF, the active ingredients of the formula are mainly involved in transcription factor binding, protein homodimerization activity, nuclear receptor activity, cytokine activity, protein kinase binding, kinase regulator activity, oxidoreductase activity, ubiquitin-like protein ligase binding, protein domain specific binding, protease binding, etc. ( Figure 3 ).
[0056] In terms of CC, the active ingredients of the formula are mainly involved in membrane rafts, membrane side, receptor complex, platelet alpha granule, transcription regulator complex, endocytic vesicle, endoplasmic reticulum lumen, extracellular matrix, nuclear envelope ( Figure 4 ).
[0057] Experimental Example 2:
[0058] Experimental animals: 8-week-old ICR mice, SPF grade, female, 24±2g, purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. (License No. SCXK (Beijing) 2009-0010), experimental animal quality certificate No. 110324231104682227, 110324231104682112. They were kept in the animal room of Beijing Physical and Chemical Analysis and Testing Center, with a temperature of 24±2℃, humidity of 45%-55%, 12h light and dark alternation, and free access to sterile water. All animal-related procedures were carried out in accordance with the regulations of the Protection and Use Committee of Beijing Physical and Chemical Analysis and Testing Center, and in accordance with the "Guidelines for the Care and Use of Laboratory Animals". Beijing Physical and Chemical Analysis and Testing Center Laboratory Animal Use License No.: SYXK (Beijing) 2021-0014.
[0059] Experimental reagents: edible starch (Hebei Gufu Food Co., Ltd.); acarbose (Bayer Healthcare Co., Ltd.); blood glucose meter (Roche); blood glucose test strips (Roche).
[0060] Starch preparation: Weigh 10 g of starch, add 100 mL of water, and after it is fully dissolved, place in a 100°C water bath and gelatinize for 30 minutes.
[0061] Animal experiment method: 40 female SPF-grade 8-week-old ICR mice were randomly divided into 4 groups according to body weight: blank control group, starch group, acarbose group (50 mg / kg), and formula (decoction of the food and medicine homologous composition prepared in Example 1, 2.92 g / kg). There were 10 mice in each group. The blank control group and starch group were given sterile water, and the formula group was given the corresponding formula. The drug was administered for 6 days, with a dosage of 20 mL / kg, once a day. The general condition of the mice was observed every day.
[0062] On the 7th day of administration, the indexes were tested. Before the experiment, the mice were fasted but not watered for 12 hours, and the limit fasting blood glucose was measured before administration as the blood glucose at 0 min after the meal. Mice in the blank control group, starch group, acarbose group, and formula group were orally gavaged with 20 mL / kg·bw of the corresponding water / formula solution for 30 minutes, and then gavaged with 1.5 g / kg·bw of starch solution. The tail vein blood glucose of mice was measured with a blood glucose meter 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes after starch gavage, and the area under the blood glucose curve was calculated.
[0063] Data statistics: SPSS 23.0 was used for statistical analysis, and the results were expressed as Mean ± SD. The data within the group conformed to the normal distribution, and the mean of multiple groups of samples was compared by one-way analysis of variance (ANOVA). The LSD test was used for homogeneous variances, and the Dunnett's T3 test was used for unequal variances. P < 0.05 was considered statistically significant.
[0064] The general condition of the mice was observed every day during the drug administration period, and no obvious abnormalities were found in the mice in the blank group and each drug administration group. Blood glucose was tested after the mice were gavaged with starch. Figure 5 As shown in the figure, compared with the blank control group, the tail vein blood glucose of the model group mice at 15min, 30min, 45min, and 60min after starch feeding was significantly increased (P<0.01, P<0.01, P<0.01, P<0.01), indicating that the blood glucose of mice increased significantly after starch feeding. Compared with the model group, the positive drug acarbose can significantly reduce the blood glucose of mice at 15min, 30min, and 45min after starch feeding (P<0.01, P<0.01, P<0.01), indicating that acarbose can relieve postprandial hyperglycemia, further proving the accuracy of the experimental operation; the food and medicine homologous formula can reduce the blood glucose of mice at 15min and 30min after starch feeding (P<0.05, P<0.05), indicating that the food and medicine homologous formula can significantly reduce the hyperglycemic effect of carbohydrates.
[0065] The same animal experiment was continued on the decoction of the food-drug homologous composition prepared in Examples 1-3 and Comparative Examples 1-4, wherein Example 1 was administered with a medium dose (5.83 g / kg), and the tail vein blood glucose of mice was measured with a blood glucose meter 30 minutes after starch gavage. The measurement results are shown in Table 1:
[0066] Table 1 Effect of food-drug combination on starch-induced blood glucose elevation in mice
[0067]
[0068]
[0069] Note: Compared with the group in Example 1, *P<0.05.
[0070] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A food-drug combination for lowering blood sugar, characterized in that: The invention comprises the following components: polygonatum, kudzu root, polygonatum odoratum, mulberry leaf, bergamot, citron, mulberry, ebony, daidaihua and jujube seed.
2. The food-drug homologous composition for lowering blood sugar according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 5-10 parts of polygonatum, 5-10 parts of kudzu root, 5-10 parts of polygonatum odoratum, 3-10 parts of mulberry leaf, 3-5 parts of citron, 3-5 parts of mulberry, 3-5 parts of ebony, 3-5 parts of daisy flower and 3-5 parts of spiny jujube seed.
3. The food-drug homologous composition for lowering blood sugar according to claim 2, characterized in that: The invention comprises the following components in parts by weight: 7.5 parts of polygonatum, 7.5 parts of kudzu root, 7.5 parts of polygonatum odoratum, 5 parts of mulberry leaf, 4 parts of bergamot, 4 parts of citron, 4 parts of mulberry, 4 parts of ebony, 4 parts of daidai hua and 4 parts of spiny jujube seed.
4. The blood sugar-lowering food-drug homologous composition according to claim 1, characterized in that: The raw material medicine according to claim 1 is decocted and extracted with water to prepare an oral solution.
5. The blood sugar lowering food and medicine composition according to claim 1, characterized in that: The raw material drug according to claim 1 is crushed into fine powder and mixed to form a powder.
6. The food-drug homologous composition for lowering blood sugar according to claim 1, characterized in that: The raw material medicine according to claim 1 is crushed into fine powder and filled into capsules to prepare capsules.
7. The food-drug homologous composition for lowering blood sugar according to claim 1, characterized in that: The raw material drug according to claim 1 is crushed into fine powder and compressed into tablets.
8. The food-drug homologous composition for lowering blood sugar according to claim 1, characterized in that: The raw material medicine according to claim 1 is extracted by decocting with water, and the extract is concentrated to form granules to form granules; or, the raw material medicine according to claim 1 is extracted by decocting with water, and the extract is concentrated to form granules, and the granules are encapsulated to form capsules; or, the raw material medicine according to claim 1 is extracted by decocting with water, and the extract is concentrated to form granules, and the tablets are formed.
9. A food, characterized in that The invention comprises the food-drug homologous composition or its extract as claimed in claim 1; the food is a liquid beverage, a solid beverage, a rice sauce, a compressed candy, a jelly or a soft candy.